Skip to main content
Premium Trial:

Request an Annual Quote

EMD Chemicals Signs License with Luminex to Develop Assays for xMAP

NEW YORK (GenomeWeb News) - Luminex has granted EMD Chemicals, a subsidiary of Germany’s Merck KGaA, a license to develop multiplex immunoassays for the xMAP technology platform, EMD said last week.
 
EMD said it plans to develop multiplex assays for the xMAP under its Novagen brand to detect the phosphorylation status of proteins in disease-related signaling pathways.
 
EMD’s VP of corporate development, Lisa Johnson, said the advantages of multiplex protein analysis include the ability to perform different assays on one sample in single reaction results, which saves time and samples and reduces labor and reagent costs.
 
Financial terms of the agreement were not released.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.